Dr. Amitkumar Mehta, MD
Claim this profileUniversity of Alabama at Birmingham
Expert in Lymphoma
Studies Non-Hodgkin's Lymphoma
15 reported clinical trials
26 drugs studied
Area of expertise
1Lymphoma
Global LeaderStage I
Stage II
Stage IV
2Non-Hodgkin's Lymphoma
CD19 positive
Affiliated Hospitals
Clinical Trials Amitkumar Mehta, MD is currently running
AB-101 + Immunotherapy
for Non-Hodgkin's Lymphoma
AB-101 is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells. White blood cells are part of the immune system and NK cells are a type of white blood cell that are known to kill cancer cells. This clinical trial will enroll patients with relapsed/refractory non-Hodgkin lymphoma of B-cell origin and is conducted in two phases. The primary objectives of Phase 1 are as follows: 1) to evaluate the safety of AB-101 given alone or in combination with rituximab (including the DLBCL specific cohort) or in combination with bendamustine and rituximab; 2) to evaluate the potential clinical activity of AB-101 when given in combination with rituximab or in combination with bendamustine and rituximab (combination cohorts only); and 3) to identify the recommended Phase 2 dose (RP2D). The primary objective of Phase 2 is to determine whether AB-101 in combination with rituximab or in combination with bendamustine and rituximab has anti-cancer activity in patients. Patients will be assigned to receive either AB-101 alone as monotherapy, in combination with rituximab (including DLBCL specific cohort) or in combination with bendamustine and rituximab. All patients will receive at least 1 treatment cycle of AB-101, followed by scheduled assessments of overall health and tumor response. Patients receiving AB-101 in combination with rituximab may receive up to 3 additional cycles of treatment. Patients receiving AB-101 in combination with bendamustine and rituximab may receive up to 5 additional cycles of treatment. Patients enrolled into the DLBCL specific cohort receiving AB-101 in combination with rituximab may receive up to 3 cycles of treatment.
Recruiting1 award Phase 1 & 24 criteria
JCAR017
for Chronic Leukemia or Lymphoma
This trial tests JCAR017, a therapy using modified immune cells, in adults with hard-to-treat CLL or SLL. It aims to see if these enhanced immune cells can better fight the cancer.
Recruiting1 award Phase 1 & 2
More about Amitkumar Mehta, MD
Clinical Trial Related11 years of experience running clinical trials · Led 15 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Amitkumar Mehta, MD has experience with
- Rituximab
- Brentuximab Vedotin
- IPH4102
- ASTX660
- CC-95251
- Cetuximab
Breakdown of trials Amitkumar Mehta, MD has run
Lymphoma
Non-Hodgkin's Lymphoma
Peripheral T-Cell Lymphoma
B-Cell Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Amitkumar Mehta, MD specialize in?
Amitkumar Mehta, MD focuses on Lymphoma and Non-Hodgkin's Lymphoma. In particular, much of their work with Lymphoma has involved Stage I patients, or patients who are Stage II.
Is Amitkumar Mehta, MD currently recruiting for clinical trials?
Yes, Amitkumar Mehta, MD is currently recruiting for 5 clinical trials in Birmingham Alabama. If you're interested in participating, you should apply.
Are there any treatments that Amitkumar Mehta, MD has studied deeply?
Yes, Amitkumar Mehta, MD has studied treatments such as Rituximab, Brentuximab Vedotin, IPH4102.
What is the best way to schedule an appointment with Amitkumar Mehta, MD?
Apply for one of the trials that Amitkumar Mehta, MD is conducting.
What is the office address of Amitkumar Mehta, MD?
The office of Amitkumar Mehta, MD is located at: University of Alabama at Birmingham, Birmingham, Alabama 35294 United States. This is the address for their practice at the University of Alabama at Birmingham.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.